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Background: The library size is critical for selection in evolutionary molecular engineering (directed evolution).
Although cDNA display has become a promising in vitro display technology by overcoming the instability of mRNA
display, it is hindered by low yields. In this study, we improved the yield of cDNA display molecules by carefully
examining each step of the preparation process.
Findings: We found that steric hindrance of ribosomes binding to the mRNA-protein fusion molecules was
interfering with biotin-streptavidin binding. Additionally, reducing buffer exchange by performing RNase digestion
in the His-tag-binding buffer to release the cDNA display molecules improved their His-tag purification.
Conclusion: Our optimized conditions have improved the yield of cDNA display molecules by more than 10 times
over currently used methods, making cDNA display more practically available in evolutionary molecular
engineering.
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For nearly two decades, evolutionary molecular engin-
eering (directed evolution) has played a role as a com-
plementary partner to rational protein design in protein
engineering [1]. In evolutionary molecular engineering,
the size of the library is crucial for selection efficiency.
Recently, the productivity and versatility of in vitro dis-
play technologies have increased the size of libraries by
using a cell-free translation system. For example, ribo-
some [2] and mRNA displays [3,4] have large libraries
because the amount of mRNA-peptide/protein (geno-
type-phenotype) complex with a ribosome or puromycin
is proportional to the input of mRNA (~1012/ml) in a
cell-free translation system. In the case of mRNA dis-
play, ligation methods have been developed to synthesize
mRNA-puromycin-linker practically [5-7]. However, es-
sentially the lability of mRNA in both ribosome and
mRNA displays has restricted the experimental selection
conditions.
Thus, the cDNA display method was developed to
improve the stability by converting mRNA to cDNA with a
novel puromycin-linker [8]. This technology allows* Correspondence: nemoto@fms.saitama-u.ac.jp
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reproduction in any medium, provided the orresearchers to screen large combinatorial libraries against
molecules on a cell surface (e.g. receptors) [9], and to use
peptide libraries containing two or more disulfide bonds
[10,11]. Although the cDNA display method was useful for
in vitro peptide and protein selection, its productivity was
hindered by the generation of mRNA/cDNA-protein fusion
molecules; only around 0.1% of the initial mRNA was ligated
to proteins with a puromycin-linker [8]. Recently, this effi-
ciency has been improved to more than 1% by introduction
of a novel puromycin-linker and minor modification of pre-
vious method [12,13]. However, the yield of cDNA display
fusion molecules is still smaller than that of mRNA display
fusion molecules (20–30%).
The aims of this study were to investigate which pro-
cesses during the preparation of cDNA display fusion
molecules shown in Figure 1 cause its low yield, and to in-
crease the yield by overcoming these problems.
First, we determined the binding capacity of streptavidin-
coated magnetic beads (SA-beads) (Dynabeads MyOne
streptavidin C1 streptavidin magnetic beads, Invitrogen,
Carlsbad, CA, USA) sufficient to collect most of the
mRNA-protein fusion molecules from the rabbit reticulo-
cyte lysate. In our previous study, SA-beads with a binding
capacity of 360 pmol of biotinylated DNA primers were
used for purifying of 48 pmol of mRNA-linker conjugatesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Preparation method of cDNA display. (A) Scheme of cDNA display preparation. The mRNA-linker conjugate was prepared by ligation
of a puromycin-linker to the 3’-terminus of an mRNA coding B-domain of protein A (BDA). The mRNA-linker conjugate was translated by an
in vitro translation reaction. The produced mRNA-protein fusion molecule and the remaining mRNA-linker conjugate were captured with
SA-beads from the translation reaction mixture and reverse transcribed on the beads. The mRNA/cDNA-protein fusion molecule and the mRNA/
cDNA molecule were released from the SA-beads by RNase T1 treatment. The mRNA/cDNA-protein fusion molecule was purified by the His-tag
in the translated protein. (B) Schematic diagram of construct of short biotin segment puromycin-linker (SBP-linker). The SBP-linker construct
comprises four parts: a ligation site for mRNA, a primer region for reverse transcription, a biotin moiety for the immobilization of the mRNA-linker
conjugate on Streptavidin-beads, and two cleavage sites for RNase T1 to release the mRNA/cDNA-protein fusion molecule from the SA-beads. In
addition, the SBP-linker includes puromycin (for the covalent linking of the expressed protein to mRNA) and fluorescein (for detection and
quantification). The 3’-region of the mRNA is shown in lower case letters. [N-(6-maleimidcaproyloxy) succinimide] (EMCS) is bifunctional






























Figure 2 Effect of EDTA treatment on the capturing of mRNA-protein fusions by SA-beads. mRNA-protein fusion molecules in the
translation reaction mixture with (+) or without (−) EDTA were incubated with SA-beads [the ratio of the biotin-binding capacity of the SA-beads
to the total amount of puromycin-linker conjugate is 200 to 1]. (A) The remaining mRNA-protein fusion molecules in each translation reaction
mixture were analyzed by 4% stacking–6% separating SDS PAGE containing 8 M urea. The input mRNA-linker conjugates and translation reaction
mixture are shown in lane I and lane T, respectively. (B) Binding efficiencies are calculated by: [band intensity of the mRNA-protein fusion
molecules in lane T] - [band intensity of the remaining mRNA-protein fusion molecules in each lane indicated by “+” or “–” EDTA].
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Figure 3 Optimization of the amount of SA-beads to bind the mRNA-protein fusion molecules. (A) mRNA-protein fusion was prepared
from DNA template coding B domain of protein A (BDA) using SBP-linker as described Figure 1. Translation mixture was treated with EDTA same
as Figure 2. Then the mixture was incubated with 0.0075–0.2 mg of SA-beads per 0.5 pmol of mRNA estimated from the amount in the ligation
reaction [the ratio of the biotin-binding capacity of the SA-beads to the total amount of SBP-linker (containing a single biotin) is 7.5–200].
Inputted mRNA-linker conjugates (lane I), translation mixture (lane T), and remaining mRNA-protein fusion molecules in the translation mixture
after incubation with different amounts of SA-beads were analyzed by 4% stacking–6% separating SDS-PAGE containing 8 M urea. (B) Binding
efficiencies of each ratio were calculated by: [band intensity of the mRNA-protein fusion molecules in lane T] - [band intensity of the remaining
mRNA-protein fusion molecules in each lane indicated by SA-beads]. Experiments were repeated 3 times. Error bars = standard deviation. (C)
mRNA/cDNA-protein fusion molecules were prepared with each ratio of SA-beads. Reverse transcription (RT) was performed at 40°C for at least
10 min in 20 μL of the RT reaction mixture [50 mM Tris–HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2, 50 mM dithiothreitol (DTT), 0.5 mM dNTP mix and
200 U of SuperScriptIII reverse transcriptase (Invitrogen)] . 20 U of RNase T1 (Ambion) and RNase H (Takara Bio Inc., Kyoto, Japan) were added to
the RT reaction mixture and incubated at 37°C for 10 min. Released mRNA/cDNA-protein fusion molecules were confirmed by SDS-PAGE as the
above. (D) The amount of cDNA-protein fusion molecules calculated by comparing the band intensity between the cDNA-protein fusion
molecule of each lane and 0.5 pmol of mRNA-linker conjugate.
Arrow 3: cDNA-linker conjugate
Arrow 2: mRNA-protein fusion molecule
Arrow 1: mRNA-linker conjugate
Arrow 4: cDNA-protein fusion molecule
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Figure 4 Effect of His-tag-binding buffer in RNase T1 digestion and His-tag purification to recover mRNA/cDNA-protein fusion
molecules from SA-beads. (A) cDNA-protein fusion molecules were synthesized and released from the SA-beads by RNase T1 treatment in RT
reaction mixture or His-tag-binding buffer (20 mM Sodium phosphate, pH 7.4, 500 mM NaCl, 5 mM imidazole, 0.05% Tween-20). cDNA-protein
fusions in the each sample were purified with 20 μL of Ni-NTA beads (His Mag Sepharose Ni, GE Healthcare Bio-Sciences, Piscataway, NJ, USA)
according to the attached instruction. Inputted mRNA-linker conjugates (lane I), translation mixture (lane T), each supernatant (Sup.) of Ni-NTA
beads and eluate were analyzed by 4% stacking–6% separating SDS-PAGE containing 8 M urea. (B) Formation efficiencies of mRNA/cDNA-protein
fusion molecules from mRNA-linker-conjugates were estimated by comparing the band intensities between the purified cDNA-protein fusion
molecule of each lane and that of the mRNA-linker conjugate (lane I). Results are the mean of three independent experiments performed in
duplicate. Error bars = standard deviation.
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for capturing this amount of biotinylated mRNA-protein fu-
sion molecules, but the final yield of mRNA/cDNA-protein
fusion molecule was much lower than expected. We specu-
lated that ribosomes might strongly bind the mRNA-protein
complex in the lysate before purification with the SA-beads.
Indeed, we found that Ethylenediaminetetraacetic acid
(EDTA) treatment for releasing ribosomes was effective to
purify mRNA-protein fusion molecules from the translation
mixture (Figure 2A, B). And in the present study, we found
that SA-beads with a binding capacity 200 times the amount
of biotinylated mRNA-protein fusion molecules were
required to purify almost the all fusion molecules
(Figure 3A, B). Similarly, the final amount of purified
cDNA-protein fusion molecules also increased with in-
creased SA-beads (Figure 3C, D). These results suggest that
steric hindrance might interfere with biotin-streptavidin
binding considerably.
Second, we optimized the process from RNase T1 diges-
tion to His-tag purification of cDNA display molecules
shown in Figure 1A. In the cDNA display method, it is very
important to separate mRNA/cDNA-protein fusion mole-
cules from mRNA/cDNA-linker conjugates (which are not
fused with its coding proteins) to reduce the background in
the in vitro selection. Thus His-tag sequence (His X6) was
incorporated to the C-terminal region of a coding protein.
In this study we examined whether RNase T1 can digest the
guanine base of the SBP-linker in the His-tag-binding buffer
containing imidazole. If possible, buffer exchange for
His-tag purification after RNase T1 digestion would be
eliminated and so there could be no loss of cDNA display
molecules. We found that RNase T1 worked well in the
His-tag-binding buffer, and cDNA-protein fusion molecules
were efficiently purified by His-tag purification without any
buffer exchanges (Figure 4A, B). As a result, this modifica-
tion increased the yield of mRNA/cDNA-protein fusion
molecules by 1.5 times over the previous method. Moreover,
this improvement allows us to save time and cost in the
preparation of mRNA/cDNA-protein fusion molecules and
to help make cDNA display technology easier to use.
One of the crucial problems with cDNA display is the
low yield of cDNA-protein fusion molecules, which is
less than 1% of input mRNA-linker conjugates [8,12]. In
this paper, we identified that the mRNA-ribosome-protein
complex may sterically hinder the biotin-streptavidin inter-
action between the puromycin-linker on the fusion mole-
cules and the SA-beads. In addition, mRNA-protein fusion
molecules without a ribosome could also interfere with the
biotin-streptavidin interaction. Because of these reasons,
more SA-beads than expected are required to purify most of
the mRNA-protein fusion molecules. The addition of EDTA
into the lysate after translation to remove the bound ribo-
some effectively increased the yield of cDNA display mole-
cules. Furthermore, the simplification of His-tag purificationafter the release of cDNA display molecules from the SA-
beads by performing RNase T1 digestion in the His-tag-
binding buffer also increased the yield of cDNA display
molecules. Finally we achieved 17% of final yield of cDNA
display molecule based on the input mRNA-linker conju-
gates (Figure 4B), which is more than 10 times higher than
in our previous study [8,12]. Additionally, we recently also
succeeded in releasing cDNA display molecules from SA-
beads by using Endonuclease V instead of RNase T1 by de-
signing a new puromycin-linker [14]. Thus, we believe that
this new linker and our currently optimized conditions will
make cDNA display more useful and practical for in vitro
protein selection.
Abbreviations
SA-beads: Streptavidin-coated magnetic beads; BDA: B domain of protein A;
SBP-linker: Short biotin segment puromycin-linker; EMCS: N-(6-
maleimidcaproyloxy) succinimide; EDTA: Ethylenediaminetetraacetic acid;
RT: Reverse transcription; DTT: Dithiothreitol; SDS-PAGE: Dodecyl sulfate–
polyacrylamide gel electrophoresis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YM and NN designed the study. YM and SK performed the experiments. YM,
SK and NN analyzed the data and KN assisted with data interpretation. YM
and NN contributed to the writing of the manuscript. All authors approved
the manuscript.
Acknowledgments
This work was supported by the Core Research for Evolutional Science and
Technology (CREST) program of the Japan Science and Technology Agency
(JST) and JSPS KAKENHI Grant Number 23510253.
Received: 17 April 2013 Accepted: 19 May 2013
Published: 22 May 2013
References
1. Chica RA, Doucet N, Pelletier JN: Semi-rational approaches to engineering
enzyme activity: combining the benefits of directed evolution and
rational design. Curr Opin Biotech 2005, 16:376–384.
2. Hanes J, Plückthun A: In vitro selection and evolution of functional
proteins by using ribosome display. Proc Natl Acad Sci U S A 1997,
94:4937–4942.
3. Nemoto N, Miyamoto-Sato E, Husimi Y, Yanagawa H: In vitro virus:
bonding of mRNA bearing puromycin at the 3'-terminal end to the
C-terminal end of its encoded protein on the ribosome in vitro.
FEBS Lett 1997, 414:405–408.
4. Roberts RW, Szostak JW: RNA-peptide fusions for the in vitro selection of
peptides and proteins. Proc Natl Acad Sci U S A 1997, 94:12297–12302.
5. Liu R, Barrick JE, Szostak JW, Roberts RW: Optimized synthesis of
RNA-protein fusions for in vitro protein selection. Methods Enzymol 2000,
318:268–293.
6. Kurz M, Gu K, Lohse PA: Psoralen photo-crosslinked mRNA-puromycin
conjugates: a novel template for the rapid and facile preparation of
mRNA-protein fusions. Nucleic Acids Res 2000, 28:E83.
7. Tabuchi I, Soramoto S, Suzuki M, Nishigaki K, Nemoto N, Husimi Y: An
efficient ligation method in the making of an in vitro virus for in vitro
protein evolution. Biol Proced Online 2002, 4:49–54.
8. Yamaguchi J, Naimuddin M, Biyani M, Sasaki T, Machida M, Kubo T, Funatsu
T, Husimi Y, Nemoto N: cDNA display: a novel screening method for
functional disulfide-rich peptides by solid-phase synthesis and
stabilization of mRNA-protein fusions. Nucleic Acids Res 2009, 37:108.
9. Ueno S, Yoshida S, Mondal A, Nishina K, Koyama M, Sakata I, Miura K,
Hayashi Y, Nemoto N, Nishigaki K, Sakai T: In vitro selection of a novel
Mochizuki et al. Biological Procedures Online 2013, 15:7 Page 5 of 5
http://www.biologicalproceduresonline.com/content/15/1/7peptide antagonist of growth hormone secretagogue receptor using
cDNA display. Proc Natl Acad Sci U S A 2012, 109:11121–11126.
10. Naimuddin M, Kobayashi S, Tsutsui C, Machida M, Nemoto N, Sakai T, Kubo
T: Directed evolution of a three-finger neurotoxin using cDNA display
yields antagonists as well as agonists of interleukin-6 receptor signaling.
Mol Brain 2011, 4:2.
11. Nemoto N, Tsutsui C, Yamaguchi J, Ueno S, Machida M, Kobayashi T, Sakai
T: Antagonistic effect of disulfide-rich peptide aptamers selected by
cDNA display on interleukin-6-dependent cell proliferation.
Biochem Biophys Res Commun 2012, 421:129–133.
12. Mochizuki Y, Biyani M, Tsuji-Ueno S, Suzuki M, Nishigaki K, Husimi Y,
Nemoto N: One-pot preparation of mRNA/cDNA display by a novel and
versatile puromycin-linker DNA. ACS Comb Sci 2011, 13:478–485.
13. Ueno S, Nemoto N: cDNA display: rapid stabilization of mRNA display.
Methods Mol Biol 2012, 805:113–35.
14. Ueno S, Kimura S, Ichiki T, Nemoto N: Improvement of a puromycin-linker
to extend the selection target varieties in cDNA display method.
J Biotechnol 2012, 162:299–302.
doi:10.1186/1480-9222-15-7
Cite this article as: Mochizuki et al.: Increasing the library size in cDNA
display by optimizing purification procedures. Biological Procedures Online
2013 15:7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
